PAHC Phibro Animal Health
- 17.160
- +0.040+0.23%
- 18.000
- +0.840+4.90%
Phibro Animal Health News
Barclays: Maintaining the Phibro Animal Health (PAHC.US) rating, adjusted from reduced holdings to reduced holdings rating, and adjusted the target price from $10.00 to $13.00.
Phibro Animal Health Analyst Ratings
Barclays Maintains Underweight on Phibro Animal Health, Raises Price Target to $13
Analysts' Opinions Are Mixed on These Healthcare Stocks: Cytokinetics (CYTK), Phibro Animal Health (PAHC) and Amphastar Pharmaceuticals (AMPH)
Analysts Offer Insights on Healthcare Companies: Omnicell (OMCL), Replimune Group (REPL) and Phibro Animal Health (PAHC)
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), BridgeBio Pharma (BBIO) and Phibro Animal Health (PAHC)
Underperform Rating for Phibro Animal Health: Analysis of Q1 Results and Future Challenges
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $16
Phibro Animal Health Analyst Ratings
Roth MKM Reiterates Buy on Phibro Animal Health, Maintains $21 Price Target
Phibro Animal Health Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Phibro Animal Health, Lowers Price Target to $17
Phibro Animal Health Analyst Ratings
Analysts Conflicted on These Healthcare Names: BioMarin Pharmaceutical (BMRN) and Phibro Animal Health (PAHC)
Analysts Offer Insights on Healthcare Companies: Chemed (CHE), Phibro Animal Health (PAHC) and Catalent (CTLT)
Roth MKM Reiterates Buy on Phibro Animal Health, Maintains $21 Price Target
Phibro Animal Health Analyst Ratings
Morgan Stanley Reiterates Equal-Weight on Phibro Animal Health, Maintains $18 Price Target
Phibro Animal Health Analyst Ratings
Morgan Stanley Adjusts Price Target on Phibro Animal Health to $18 From $19, Maintains Equal-Weight Rating
Analysis
Price Target
No Data
